http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이경천,고복영,유정훈 부천대학 2004 論文集 Vol.25 No.-
산업혁명 이후 급속한 경제발전에 따른 사회간접시설공사의 확대와 더불어 가속화된 환경오염으로 인한 직접적인 피해가 가시화됨에 따라 인류의 지구환경에 대한 관심이 점차 확대되어 환경보호정책이 점점 강화되고 있는 실정이다. 이러한 지구환경을 보존하기 위해 인류는 자원 및 에너지의 낭비를 개선하고, 자원 순환형 사회를 구축하기 위해 산업 폐기물의 자원재활용 시스템을 확립하고, 사용자 입장에서 재활용 재료의 적극적인 이용이 바람직하다. 현시점에서 슬래그와 같은 산업부산물, 콘크리트 폐기물과 건설폐자재 등과 같은 건설부산물을 재활용하는 폐기물의 자원화는 기업의 생산 공정에 요구되는 중요한 환경친화적 기술 중 하나이므로 대학 및 연구소를 위주로 활발히 검토되고 있다. 그러나 현재 고부가가치로 많이 활용되고 있는 고로슬래그와는 달리 국내에서 연간 약 650만 톤 배출되어지는 제강슬래그는 정련과정에서 용융되지 않아서 그대로 잔류한 유리석회(free CaO)가 원인이 되어 팽창 붕괴가 발생하여 아직도 유효이용이 되지 않고 있는 실정이다. 따라서 불안정한 제강슬래그를 사용 전 공기 중에 방치하여 유리석회의 팽창 붕괴작용을 진행시키는 에이징 처리가 국내외적으로 널리 행하여지고 있다. 본 연구는 먼저 에이징 처리 방법에 대한 참고문헌 및 자료 등을 검토하고 팽창성이 있어서 콘크리트용 골재로 사용에 제한이 있는 전로 및 전기로슬래그를 촉진에이징 처리에 의해 안정화시킨 후 전로 및 전기로슬래그 골재의 잔류 팽창성을 확인하였다. 그리고 에이징 처리한 전로슬래그 골재의 화학 및 물리적 변화를 기기분석에 의해 검토하였고 전로 및 전기로슬래그의 콘크리트용 골재로서의 품질을 KS 규격에 근거하여 시험하여 콘크리트용 골재로서의 가능성 및 품질에 대해 고찰하고자 한다. Generally natural aggregate is relatively stable and does not enter into complex chemical reactions with water. Unfortunately, however, converter and electric arc furnace slag aggregate contain a small amount of free lime. The hydration of lime makes converter and electric arc furnace slag aggregate unstable and liable to expand. Therefore converter and electric arc furnace slag are not provided for concrete aggregate. The expansion of converter and electric arc furnace slag aggregate processed by hotwater or steam aging is much lower than that of non aging. The reason is that the unstable free CaO inside non aged converter and electric arc furnace slag aggregate reacts with H₂0. In this paper, firstly, several aging methods were used in order to decrease the volume expansion of converter and electric arc furnace slag aggregate, that is stabilization. Aged converter and electric arc furnace slag aggregates were compared with natural and crushed aggregate in properties for concrete, specific gravity, absorption, unit weight, percentage of solids and soundness.
Traditional herbal medicine for cancer pain: A systematic review and meta-analysis
Lee, Jung-Woo,Lee, Won Bock,Kim, Woojin,Min, Byung-Il,Lee, HyangSook,Cho, Seung-Hun Elsevier 2015 Complementary Therapies in Medicine Vol.23 No.2
<P><B>Summary</B></P> <P><B>Background</B></P> <P>The effectiveness of traditional herbal medicine (THM) as an adjunctive therapy for cancer pain is unclear.</P> <P><B>Objective</B></P> <P>To assess the effectiveness of THM as an adjunctive therapy for cancer pain using randomized controlled trials (RCTs).</P> <P><B>Methods</B></P> <P>Five electronic databases, including those from the UK and China, were systematically searched for the period before September 2013. All RCTs involving the use of THM in combination with conventional cancer therapy for cancer pain were included.</P> <P><B>Results</B></P> <P>Twenty-four RCTs involving 4889 patients with cancer pain were systematically reviewed. Among them, nine studies of 952 patients reported a significant decrease in the number of patients with cancer pain in the treatment group. Four studies of 1696 patients reported a significant decrease in the degree of pain in the treatment group.</P> <P><B>Conclusion</B></P> <P>The results of these studies suggest that THM combined with conventional therapy is efficacious as an adjunctive therapy for patients with cancer pain. However, more research, including well-designed, rigorous, and larger clinical trials, are necessary to address these issues.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Integrative THM and conventional therapy for cancer pain are systematically reviewed. </LI> <LI> Significant decrease in the number of patients with pain in integrative therapy. </LI> <LI> Significant decrease in the degree of pain in integrative therapy. </LI> <LI> Integrative THM and conventional therapy are efficacious for cancer pain. </LI> </UL> </P>
Lee, Sang Jin,Heo, Dong Nyoung,Moon, Ji-Hoi,Park, Ha Na,Ko, Wan-Kyu,Bae, Min Soo,Lee, Jung Bok,Park, Se Woong,Kim, Eun-Cheol,Lee, Chang Hoon,Jung, Bock-Young,Kwon, Il Keun American Scientific Publishers 2014 Journal of Nanoscience and Nanotechnology Vol.14 No.10
<P>Electrospun chitosan (CTS) nanofibers have been well known for use as a wound dressing in the biomedical field. Nevertheless, fatal bacterial infections are still a serious problem when CTS nanofibers are used for wound treatment. In this study, we designed a novel wound dressing based on blending the chitosan with polyurethane (CTS/PU) containing silver sulfadiazine (AgSD) in order to enhance both antibacterial activity and mechanical strength. This fiber sheet was produced using the electrospinning (ELSP) technique. The CTS/PU containing AgSD fiber sheet was characterized by energy-dispersive X-ray spectroscopy (EDX). The physicochemical properties of the CTS/PU/AgSD fiber sheets were also characterized by thermogravimetric analysis (TGA) and Fourier transform infrared spectroscopy (FT-IR). The electrospun fibers were morphologically characterized by scanning electron microscopy (SEM) and transmission electron microscopy (TEM). For an in vitro evaluation, the CTS/PU/AgSD fiber sheets were tested for their antibacterial activity against gram-negative Pseudomonas aeruginosa (P. aeruginosa), gram-positive Staphylococcus aureus (S. aureus) and Methicillin-resistant Staphylococcus aureus (MRSA). The results indicate that CTS/PU/AgSD fiber sheets have strong antimicrobial activity as displayed by inhibition of bacterial growth and prevention of infection during the healing process. These results indicate that this material would be good for use as a wound dressing material.</P>
모빅 캡슐(멜록시캄 7.5㎎)에 대한 멜락스 캡슐의 생물학적동등성
이예리,염승복,고연정,고정길,김호현,이희주,이경률 한국약제학회 2004 Journal of Pharmaceutical Investigation Vol.34 No.5
A bioequivalence of Melax capsules (Chong Kun Dang Pharm., Korea) and Mobic™ capsules (Boehringer Ingelheim Korea) was evaluated according to the guideline of Korea Food and Drug Administration (KFDA). Single 15 mg dose of meloxicam of each medicine was administered orally to 24 healthy male volunteers. This study was performed in a 2 x 2 crossover design. Concentrations of meloxicam in human plasma were monitored by a high-performance liquid chromatography. AUC, (the area under the plasma concentration-time curve from time zero to 72 hr) was calculated by the linear trapezoidal rule method. C_(max) (maximum plasma drug concentration) and T_(max) (time to reach Cma,.) were compiled from the plasma concentration-time data. Analysis of variance was performed using logarithmically transformed AUC, and C_(max). No significant sequence effect was found for all of the bioavailability parameters. The 90% confidence intervals of the AUCt ratio and the C_(max) ratio for Melax™/Mobic™ were 0.95 - 1.04 and 0.98 - 1.14, respectively. This study demonstrated a bioequivalence of Melax™ and Mobic™ with respect to the rate and extent of absorption.